109 (Phospho)proteomics biomarkers for sunitinib response in RCC 47 van Alphen, C. et al. Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines. Mol Cell Proteomics 19, 884-899, doi:10.1074/mcp. RA119.001504 (2020). 48 van Linde, M. E. et al. Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research 28, 1595-1602, doi:10.1158/1078-0432.Ccr-21-1933 (2022). 49 Green, Y. S., Kwon, S. & Christian, J. L. Expression pattern of bcar3, a downstream target of Gata2, and its binding partner, bcar1, during Xenopus development. Gene Expr Patterns 20, 55-62, doi:10.1016/j.gep.2015.11.004 (2016). 50 Guo, J. M. et al. Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor beta/ Smad signaling and associates with favorable breast cancer disease outcomes. Breast Cancer Res 16, doi:ARTN 476 10.1186/s13058-014-0476-9 (2014). 51 Jenkins, N. C. et al. Genetic drivers of metastatic dissemination in sonic hedgehog medulloblastoma. Acta Neuropathol Commun 2, 85, doi:10.1186/s40478-014-0085-y (2014). 52 Wallez, Y., Riedl, S. J. & Pasquale, E. B. Association of the Breast Cancer Antiestrogen Resistance Protein 1 ( BCAR1) and BCAR3 Scaffolding Proteins in Cell Signaling and Antiestrogen Resistance. J Biol Chem 289, 10431-10444, doi:10.1074/jbc.M113.541839 (2014). 53 Zhou, K. et al. A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells. Oncotarget 8, 95377-95391, doi:10.18632/oncotarget.20709 (2017). 54 Creighton, C. J. et al. Comprehensivemolecular characterization of clear cell renal cell carcinoma. Nature 499, 43-+, doi:10.1038/nature12222 (2013). 55 Boussemart, L. et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 513, 105-+, doi:10.1038/nature13572 (2014). 56 Chen, Z. H. et al. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer. J Exp Clin Cancer Res 38, 196, doi:10.1186/s13046-019-1178-z (2019). 57 Li, Q. et al. Eukaryotic translation initiation factor 4AIII (eIF4AIII) is functionally distinct from eIF4AI and eIF4AII. Mol Cell Biol 19, 7336-7346, doi:10.1128/mcb.19.11.7336 (1999). 58 Li, Y. Z. et al. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell 41, 139-+, doi:10.1016/j.ccell.2022.12.001 (2023). 59 Tjonahen, E. et al. Resolvin E2: Identification and anti-inflammatory actions: Pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol 13, 1193-1202, doi:10.1016/j.chembiol.2006.09.011 (2006). 60 Sun, Q. Y., Zhou, H. H. & Mao, X. Y. Emerging Roles of 5-Lipoxygenase Phosphorylation in Inflammation and Cell Death. Oxid Med Cell Longev 2019, doi:Artn 2749173 10.1155/2019/2749173 (2019). 61 Casanovas, O., Hicklin, D. J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309, doi:10.1016/j.ccr.2005.09.005 (2005). 4
RkJQdWJsaXNoZXIy MTk4NDMw